Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 67,037

Document Document Title
WO/2021/018046A1
A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable ...  
WO/2021/018839A1
The present invention covers new isoquinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compou...  
WO/2021/014172A1
Compounds of general formula (I), wherein R1, R2, R3, R4, R5, X1, X2 and X3 are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.  
WO/2021/012659A1
Provided in the present invention is a compound with androgen receptor (AR) degradation activity. Specifically, provided in the present invention is a compound represented by formula (I), which is as follows, wherein the definition of ea...  
WO/2021/014415A2
The present invention relates to compounds of formula (I). The compounds may be used to modulate the acetyl coenzyme A synthetase short chain 2 (ACSS2) protein and may thereby treat, ameliorate or prevent a disease selected from cancer, ...  
WO/2021/016102A1
The present disclosure provides compounds and compositions thereof which are useful as inhibitors of tyrosine kinase and which exhibit desirable characteristics for the same. Further disclosed herein are methods of treating cancer using ...  
WO/2021/013833A1
The present invention relates to N-methyl, N-(6-(methoxy)pyridazin-3- yl) amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IFF) or systemi...  
WO/2021/013733A1
The present invention relates to a compound of formula (I): wherein: X2 represents a –CO-NRk- group, a -NR'k-CO- group, a -O- group, a -CO- group, a -SO2-group, a -CS-NH- group, a -CH2-NH-, a group, or a heterocyclyl, wherein the heter...  
WO/2021/013735A1
The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine. Formula (I)  
WO/2021/013910A1
The present invention relates to picolinic acid derivatives that are useful in treating fungal diseases, particularly in plants.  
WO/2021/013830A1
The present invention relates to N-methyl, N-(6-(methoxy)pyridazin-3- yl) amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IFF) or systemi...  
WO/2020/263967A8
This invention relates to 2H-indazole Derivatives of formula (I'), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The inventio...  
WO/2021/012018A1
The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or other...  
WO/2021/013720A1
The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations a...  
WO/2021/012864A1
Disclosed are sodium salts of pyrimidine derivatives, and a series of crystal forms thereof. The series of crystal forms exhibit a good druggability, such as stability, fluidity, compressibility, etc., and provide a variety of bulk drug ...  
WO/2021/012717A1
Disclosed are a compound as represented by general formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method therefor. Also disclosed are a pharmaceutical composition containing the compound and the use of the c...  
WO/2021/013719A1
The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations and compositions comprisin...  
WO/2021/013832A1
The present invention relates to 1-(6-(methoxy)pyridazin-3-yl) cyclopropane-1-carboxamide derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IPF) ...  
WO/2021/013800A1
The invention relates to substituted N-phenyl-N-aminouracils of general formula (I) or salts thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for co...  
WO/2021/013712A1
The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition asso...  
WO/2021/011913A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand whi...  
WO/2021/008588A1
Disclosed are a class of pyrimidine quinoline derivatives comprising prodrugs as well as a preparation method therefor and an application thereof. The structures of the pyrimidine quinoline derivatives are represented by formula (I): R1 ...  
WO/2021/011796A1
Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.  
WO/2021/008338A1
The present invention relates to a new type of pyridine compound and preparation method and application thereof. Specifically, the present invention relates to the compound represented by formula (1) and a preparation method thereof, and...  
WO/2021/009206A1
The present invention relates to a compound represented by the following Formula (I), a semiconducting layer comprising this compound, an organic electronic device comprising said organic semiconducting layer, as well as to a device comp...  
WO/2021/008491A1
Biphenyl derivatives having a structure of formula (I) and capable of blocking PD-1/PD-L1 interaction, a preparation method therefor and use thereof. The series of compounds can be widely used in the preparation of medicaments for preven...  
WO/2021/008512A1
The present invention provides a compound having N-myristoyltransferase (NMT) inhibitor activity or a pharmaceutically acceptable salt thereof and a preparation method therefor. The present invention also relates to use of such compound ...  
WO/2021/009232A1
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlli...  
WO/2021/011876A2
The present disclosure provides compounds of Formula I useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal inc...  
WO/2021/009334A2
The present invention relates to herbicidal substituted phenyl-pyridazine-diones and substituted phenyl-pyridazinone derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The ...  
WO/2020/252368A3
The present disclosure provides a novel animal model of NEHI, and method of preventing and/or treating a pulmonary disease, particularly the lung-based complications in NEHI, such as pulmonary edema, by targeting the PNEC product, such a...  
WO/2021/009209A1
Disclosed are amino triazole compounds of formula (I). These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as ...  
WO/2021/009384A1
The present invention relates to novel pyrazolone derivatives of the following formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof and to a pharmaceutical composition comprising thereof. The present invention al...  
WO/2021/011834A1
ALK5 inhibitor compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in the treating of cancer and fibros...  
WO/2021/009514A1
Described are processes for the preparation of 2,2'-di(pyridin-4-yl)-1H,1'H-5,5'- bibenzo[d]imidazole (which may also be known as 5,5'bis-[2-(4-pyridinyl)-1H- benzimidazole]), referenced herein by the INN name ridinilazole, and pharmaceu...  
WO/2021/011513A1
There are disclosed prodrugs of the compounds of the formula. The prodrugs are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.  
WO/2021/009048A1
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...  
WO/2021/007141A1
This invention relates to a process for the synthesis of a non-racemic cyclohexene compound of formula (I) by a Diels-Alder reaction of a compound of formula (II) with a compound of formula (III) wherein R1, R2, R3, R4, R5, R6, R7, R8, R...  
WO/2021/004547A1
This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for tre...  
WO/2021/004467A1
Disclosed is a class of porcupine inhibitors, specifically a compound as represented by formula (I), and a pharmaceutically acceptable salt or an isomer thereof.  
WO/2021/007477A1
The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.  
WO/2021/007155A1
The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyrid yl]benzamide hemisuccinate, and formulations and product forms mad...  
WO/2021/007350A1
This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, met...  
WO/2021/006267A1
(1) An alkyl sulfate ester salt or an alkyl sulfonic acid salt of a pyrazole derivative represented by general formula (I) [where: R represents hydrogen, an optionally substituted chain-form or cyclic hydrocarbon group or an optionally s...  
WO/2021/007307A1
Various Bcl-2 protein inhibitors are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments the Bcl-2 protein inhibitors are co...  
WO/2021/005484A1
The present invention relates to process for the preparation of a pyrrolidine compounds useful as key intermediate for the preparation of upadacitinib. More specifically the present invention relates to a process for preparing compound o...  
WO/2021/000884A1
The present invention relates to a 2-aminopyrimidine compound shown in formula I, a pharmaceutically acceptable salt, solvate or prodrug thereof, preparation methods for the 2-aminopyrimidine compound, and the pharmaceutically acceptable...  
WO/2021/003295A1
The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclo...  
WO/2021/001286A1
The present invention relates to compounds according to formula (I), which are a positive allosteric modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.  
WO/2021/003417A1
Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, m, n) are as described herein. Compounds of Formula I, pharmaceutic...  

Matches 301 - 350 out of 67,037